Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Haemoglobinopathies Market Size

The hemoglobinopathies market was valued at USD 6.9 billion in 2023, driven by the rising incidence of thalassemia and sickle cell anemia across the 8 major markets. The market is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to rise from USD 7.5 billion in 2024 to USD 15.9 billion by 2032. 

Global Haemoglobinopathies Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Haemoglobinopathies Market Outlook

  • Recent data reveals that sickle cell anemia affects approximately 100,000 United States citizens, with a higher prevalence in Black or African American individuals. This rising burden of haemoglobinopathies is expected to fuel the market demand for effective therapies.
  • Increased focus on the development of novel treatment options, such as gene therapy, which promises potential cures for genetic conditions like sickle cell disease and thalassemia, is one of the major market trends.
  • The market value is influenced by the advancements in genetic testing and screening methods, rising healthcare expenditures, and increased research funding aimed at developing new treatments.

Haemoglobinopathies Market Overview

Hemoglobinopathies are a group of inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies. It is estimated that sickle cell anemia affects approximately 100,000 United States citizens, with a higher prevalence in Black or African American individuals (1 in every 365 individuals). Consequently, the haemoglobinopathies market demand is on the rise to combat the rising incidence of diseases.

The haemoglobinopathies market is witnessing advancements in genetic testing and screening methods that are leading to early diagnosis and better management of these disorders. Increased initiatives from the government as well as non-governmental organizations are another factor supporting the market expansion. Moreover, pharmaceutical and biotechnology companies are increasingly focusing on the development and approval of novel treatment options such as gene therapy to treat sickle cell disease and thalassemia.

Haemoglobinopathies Market Growth Drivers

Increased Focus on Early Haemoglobinopathies Diagnosis to Affect the Market Landscape Significantly

The hemoglobinopathies market share is also poised to elevate with rising emphasis on detecting the condition early. In June 2023, Florida Atlantic University released its latest research on developing a portable tool to diagnose and monitor sickle cell anemia. Based on an electrical impedance sensor, the device can analyze the rate of cell sickling as well as the concentration of sickled cells in the body. It can assist in quality treatment and mitigate the comorbidities associated with the disease. The rising innovation in diagnostic capabilities and treatment monitoring is likely to bolster the market growth.

Rising Advancements in Treatment to Meet Rising Haemoglobinopathies Market Demand

The market growth is driven by advancements in treatment and diagnostics. Innovations and growth in gene therapy activities are some of the major market trends. In December 2023, the United States FDA approved Exa-cel, the first CRISPR treatment for sickle cell disease. Lovo-cel, developed by Bluebird Bio, is another gene therapy accepted by the FDA and will be used to treat sickle cell anemia in patients. The increasing integration of novel technologies to aid impactful treatment alternatives is expected to drive market growth in the coming years.

Global Haemoglobinopathies Market By Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Haemoglobinopathies Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Key Trends Impact
Rising Awareness via Screening Programs  To combat the rising incidence of hemoglobinopathies across the globe, many countries have started implementing new screening programs to detect any abnormalities at an early stage.
Surge in Strategic Partnerships and Collaborations Rising partnerships between pharmaceutical companies, healthcare providers, and research institutions are a notable market trend. The collaborations are aimed at developing effective and precise solutions for patients and are anticipated to boost the haemoglobinopathies market share.
Preference for Personalized Medicine Tailoring treatment plans based on the genetic profile of the patient is a significant trend in the market. Precision medicine can help in minimizing side effects while offering improved outcomes for patients.
Growth in Investments for Research and Development Activities To provide new diagnostic methods and treatment, there has been an increase in funding and investments by the government as well as non-governmental organizations.

Haemoglobinopathies Market Segmentation

Market Breakup by Type

  • Thalassemia
    • Alpha Thalassemia
    • Beta Thalassemia
  • Sickle Cell Disease
  • Others

Market Breakup by Therapy

  • Bone Marrow Transplant
  • Blood Transfusion
  • Iron Chelation Therapy
  • Gene Therapy
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Haemoglobinopathies Market Share

The Gene Therapy Segment is Poised to Hold Substantial Market Value

The market segmentation by therapy includes bone marrow transplant, blood transfusion, iron chelation therapy, and gene therapy, among others. The gene therapy segment is poised to attain a significant market share in the forecast period owing to its potential to cure haemoglobinopathies by directly addressing the genetic root cause. In contrast, traditional treatments like blood transfusions and iron chelation therapy can only manage symptoms which gives gene therapy a major advantage over other conventional therapies. Pharmaceutical companies and venture capitalists are heavily investing in developing gene therapies which is crucial for sustaining research and development activities necessary to bring these therapies from clinical trials to market.

Global Haemoglobinopathies Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Haemoglobinopathies Market Analysis by Region

Based on region, the market report includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to dominate the market share which can be attributed to the presence of major healthcare providers in the region, undergoing significant collaborations and acquisitions to devise the best treatment solutions. The presence of a favorable regulatory environment, such as the U.S. FDA ensuring accelerated approval of innovative treatments including gene therapies for haemoglobinopathies, further stimulates the market growth in the region. With high investments to improve the healthcare and research infrastructure, countries like India are also poised to experience rapid market growth in the forecast period.

Leading Players in the Haemoglobinopathies Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, and strategic initiatives constituting recent funding and investment, partnerships, and collaborations by the leading players. The major companies in the market are as follows:

Bluebird Bio, Inc.

Headquartered in Massachusetts (United States), Bluebird Bio, Inc., is a pioneering biotechnology company that develops gene therapies for patients suffering from severe genetic disorders. It has designed a gene therapy called LYFGENIA™ for sickle cell disease.

Emmaus Medical, Inc.

California-based Emmaus Medical, Inc. is a biopharmaceutical company and has a prominent presence in the treatment domain of sickle cell disease. ENDARI (L-glutamine oral powder) is one of its leading assets to treat sickle cell disease in patients five years of age and older. The company is actively working on expanding the availability of Endari worldwide and is poised to support the haemoglobinopathies market growth.

Prolong Pharmaceuticals, LLC.

Prolong Pharmaceuticals, LLC, headquartered in New Jersey, United States, is known for developing treatments for blood-related disorders and diseases that involve severe anemias, including haemoglobinopathies. The pharmaceutical company is engaged in the clinical development of its investigational drug products aimed at treating sickle cell disease and other conditions.

Other key players in the market include Novartis AG, Pfizer Inc., Sangamo Therapeutics, Inc., CRISPR Therapeutics AG.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Therapy
  • Region
Breakup by Type
  • Thalassemia
  • Sickle Cell Disease
  • Others
Breakup by Therapy
  • Bone Marrow Transplant
  • Blood Transfusion
  • Iron Chelation Therapy
  • Gene Therapy
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India 
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Bluebird Bio, Inc.
  • Emmaus Medical, Inc.
  • Prolong Pharmaceuticals, LLC.
  • Novartis AG
  • Pfizer, Inc. 
  • Sangamo Therapeutics, Inc.
  • CRISPR Therapeutics AG

Key Questions Answered in the Haemoglobinopathies Market Report

  • What was the haemoglobinopathies market value in 2023?
  • What is the haemoglobinopathies market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on type?
  • What are the major therapies in the market?
  • What are the major factors aiding the haemoglobinopathies market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How do the prevalence and incidence of haemoglobinopathies affect the market landscape?
  • What are the major haemoglobinopathies market trends?
  • Which haemoglobinopathies type will dominate the market share? 
  • Which test type is expected to have a high market value in the coming years?
  • Which technology type will experience the highest demand in the market segment?
  • Which therapy is projected to contribute to the highest market growth?
  • Who are the key players involved in the haemoglobinopathies market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124